SCHEMBL5277263

SCHEMBL5277263

Cc1c(N2CCC(OC(=O)N3CCNCC3)C2)c(F)cn2c(=O)c(C(=O)O)cc(C3CC3)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.38
KCNH2 Q12809 9/20 0.36
KDM4E B2RXH2 5/20 0.33
ALDH1A1 P00352 5/20 0.33
HPGD P15428 5/20 0.33
HSD17B10 Q99714 5/20 0.33
POLB P06746 1/20 0.33
PRKD3 O94806 1/20 0.33
ALOX15 P16050 1/20 0.33
OPRM1 P35372 1/20 0.33
CLK2 P49760 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 2/20 0.32
CYP1A2 P05177 1/20 0.32
TOP2A P11388 1/20 0.32
CYP2C9 P11712 1/20 0.32
TOP2B Q02880 1/20 0.32
PMP22 Q01453 1/20 0.31
HRH3 Q9Y5N1 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5571352 1.00 SCN5A (0.38) SCN5AKCNH2KDM4EALDH1A1HPGD
SCHEMBL14497211 0.91 CDK4 (0.33) SCN5AKCNH2KDM4EALDH1A1HPGD
SCHEMBL5570885 0.91 CDK4 (0.33) SCN5AKCNH2KDM4EALDH1A1HPGD
SCHEMBL8565377 0.86 SCN5A (0.44) SCN5AKCNH2KDM4EALDH1A1HPGD
SCHEMBL8575664 0.86 SCN5A (0.44) SCN5AKCNH2KDM4EALDH1A1HPGD
SCHEMBL8569539 0.86 SCN5A (0.44) SCN5AKCNH2KDM4EALDH1A1HPGD
SCHEMBL5279980 0.86 KDM4E (0.40) SCN5AKCNH2KDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL8575905 0.85 SCN5A (0.43) SCN5AKCNH2KDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL8569538 0.85 SCN5A (0.43) SCN5AKCNH2KDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL8577938 0.85 SCN5A (0.43) SCN5AKCNH2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7229996-B2 Rifamycin derivatives CUMBRE PHARMACEUTICALS INC. (US) 2007-06-12 US disclosed
EP-1781670-A1 RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS Cumbre Pharmaceuticals Inc. (US) 2007-05-09 EP disclosed
WO-2006012470-A1 RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS CUMBRE PHARMACEUTICALS INC. (US) 2006-02-02 WO disclosed
US-20060019985-A1 Rifamycin derivatives CUMBRE INC. (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019985-A1 Rifamycin derivatives RIF1, NQO1, MRM1 SCN5A 2077/4885KCNH2 2117/4885KDM4E 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.